- Home
- MTA vs PROK Comparison
MTA vs PROK Comparison
Compare MTA & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTA
- PROK
- Stock Information
- Founded
- MTA 1983
- PROK 2015
- Country
- MTA Canada
- PROK United States
- Employees
- MTA N/A
- PROK N/A
- Industry
- MTA
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MTA
- PROK Health Care
- Exchange
- MTA Nasdaq
- PROK Nasdaq
- Market Cap
- MTA 254.8M
- PROK 212.4M
- IPO Year
- MTA N/A
- PROK N/A
- Fundamental
- Price
- MTA $2.69
- PROK $1.79
- Analyst Decision
- MTA Hold
- PROK Buy
- Analyst Count
- MTA 1
- PROK 5
- Target Price
- MTA $4.50
- PROK $4.50
- AVG Volume (30 Days)
- MTA 326.3K
- PROK 537.9K
- Earning Date
- MTA 11-14-2024
- PROK 11-12-2024
- Dividend Yield
- MTA N/A
- PROK N/A
- EPS Growth
- MTA N/A
- PROK N/A
- EPS
- MTA N/A
- PROK N/A
- Revenue
- MTA $5,048,000.00
- PROK N/A
- Revenue This Year
- MTA $38.48
- PROK N/A
- Revenue Next Year
- MTA $119.30
- PROK N/A
- P/E Ratio
- MTA N/A
- PROK N/A
- Revenue Growth
- MTA 28.55
- PROK N/A
- 52 Week Low
- MTA $2.32
- PROK $1.18
- 52 Week High
- MTA $4.08
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- MTA 48.65
- PROK 53.00
- Support Level
- MTA $2.52
- PROK $1.50
- Resistance Level
- MTA $2.79
- PROK $1.90
- Average True Range (ATR)
- MTA 0.11
- PROK 0.15
- MACD
- MTA 0.03
- PROK 0.01
- Stochastic Oscillator
- MTA 68.75
- PROK 75.00
About MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.